Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Beperminogene perplasmid (Primary)
- Indications Arteriosclerosis obliterans; Thromboangiitis obliterans
- Focus Therapeutic Use
- Sponsors AnGes MG
- 23 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 01 Sep 2014 New trial record